Literature DB >> 15585706

Preoperative angiotensin-converting enzyme inhibition can cause severe post CPB vasodilation--current UK opinion.

Mohan P Devbhandari1, Sendhil K Balasubramanian, Max Codispoti, Onyekwelu C Nzewi, Sai U Prasad.   

Abstract

Preoperative use of angiotensin-converting enzyme inhibitors in cardiac surgery patients is thought to cause extreme vasodilatation in post cardiopulmonary bypass period. Opinions are divided as to whether it is beneficial or not to stop it prior to operation. A national survey in the UK was carried out on this issue. Questionnaires were sent to 167 currently practicing UK cardiac surgeons, out of which 105 (62%) replied back. Their responses were analyzed. Among the surgeons who replied to the questionnaires, the majority (63%) were of the opinion that the use of angiotensin-converting enzyme inhibitors leads to vasodilatation resulting in increased usage of fluids, inotropes and vasoconstrictors. However, there was no agreement on the issue of stopping it prior to surgery. Forty one (39%) felt it was beneficial to stop the angiotensin-converting enzyme inhibitors prior to surgery whereas 40 (38%) of them thought it was harmful to stop it. Twenty one (20%) were of the opinion that it made no difference. 39% of respondents practiced stopping the drug prior to planned operation. This national survey revealed differences in management of patients on angiotensin-converting enzyme inhibitors undergoing cardiac surgery. Recommendations from available literature are equally varied, highlighting the need for multicenter randomized trials to address this clinical problem.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585706     DOI: 10.1177/021849230401200414

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  6 in total

Review 1.  Drugs for the perioperative control of hypertension: current issues and future directions.

Authors:  Robert Feneck
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Acute kidney injury following surgical aortic valve replacement.

Authors:  Marc Najjar; Halit Yerebakan; Robert A Sorabella; Denis J Donovan; Alexander P Kossar; Sowmyashree Sreekanth; Paul Kurlansky; Michael A Borger; Michael Argenziano; Craig R Smith; Isaac George
Journal:  J Card Surg       Date:  2015-06-24       Impact factor: 1.620

3.  Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery.

Authors:  Pradeep Arora; Srini Rajagopalam; Rajiv Ranjan; Hari Kolli; Manpreet Singh; Rocco Venuto; James Lohr
Journal:  Clin J Am Soc Nephrol       Date:  2008-07-30       Impact factor: 8.237

4.  Impact of Angiotensin-converting enzyme inhibitors and Angiotensin receptor blockers on mortality of coronary artery bypass grafting.

Authors:  Ahmad Sharafi; Saeed Davoodi; Abbas Ali Karimi; Hosein Ahmadi; Kyomars Abbasi; Mahmood Sheikh Fathollahi; Payvand Bina; Maryam Soleymanzadeh; Arezoo Fehri; Saeid Davaran; Siroos Jahangheeri; Seyed Ebrahim Kassaian
Journal:  J Tehran Heart Cent       Date:  2013-10-28

5.  The Effect of Chronic Consumption of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Antagonists on Blood Pressure and Inotrope Consumption After Separation from Cardiopulmonary Bypass.

Authors:  Ebrahim Hassani; Alireza Mahoori; Nazli Karami; Asma Hassani; Leila Hassani
Journal:  Anesth Pain Med       Date:  2018-06-20

6.  Comparison of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Management Strategies Before Cardiac Surgery: A Pilot Randomized Controlled Registry Trial.

Authors:  Sean van Diepen; Colleen M Norris; Yinggan Zheng; Jayan Nagendran; Michelle M Graham; Damaris Gaete Ortega; Derek R Townsend; Justin A Ezekowitz; Sean M Bagshaw
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.